Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial

BACKGROUND: Upper extremity (UE) impairment is common with primary progressive multiple sclerosis (PPMS). OBJECTIVE: This exploratory analysis examined the effects of ocrelizumab on confirmed progression (CP) and confirmed improvement (CI) in UE impairment in patients from ORATORIO. METHODS: Patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Fox, Edward J, Markowitz, Clyde, Applebee, Angela, Montalban, Xavier, Wolinsky, Jerry S, Belachew, Shibeshih, Fiore, Damian, Pei, Jinglan, Musch, Bruno, Giovannoni, Gavin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282157/
https://www.ncbi.nlm.nih.gov/pubmed/30415593
http://dx.doi.org/10.1177/1352458518808189

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282157/
https://www.ncbi.nlm.nih.gov/pubmed/30415593
http://dx.doi.org/10.1177/1352458518808189

Ejemplares similares